205 related articles for article (PubMed ID: 2466128)
1. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
3. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
5. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K; Alm G
Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon].
Doberauer C; Niederle N; Kloke O; Kurschel E; Schmidt CG
Onkologie; 1987 Dec; 10(6):340-4. PubMed ID: 2450326
[TBL] [Abstract][Full Text] [Related]
7. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
Välimäki M; Järvinen H; Salmela P; Sane T; Sjöblom SM; Pelkonen R
Cancer; 1991 Feb; 67(3):547-9. PubMed ID: 1702352
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.
Rönnblom LE; Alm GV; Oberg KE
Ann Intern Med; 1991 Aug; 115(3):178-83. PubMed ID: 2058872
[TBL] [Abstract][Full Text] [Related]
9. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.
Oberg K; Funa K; Alm G
N Engl J Med; 1983 Jul; 309(3):129-33. PubMed ID: 6191217
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.
Doberauer C; Mengelkoch B; Kloke O; Wandl U; Niederle N
Acta Oncol; 1991; 30(5):603-5. PubMed ID: 1892678
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Smith DB; Scarffe JH; Wagstaff J; Johnston RJ
Cancer Treat Rep; 1987 Dec; 71(12):1265-6. PubMed ID: 3690534
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD
Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic carcinoid tumour with recombinant interferon alfa.
Joensuu H; Kumpulainen E; Gröhn P
Eur J Cancer; 1992; 28A(10):1650-3. PubMed ID: 1382493
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
16. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours.
Tiensuu Janson EM; Ahlström H; Andersson T; Oberg KE
Eur J Cancer; 1992; 28A(10):1647-50. PubMed ID: 1382492
[TBL] [Abstract][Full Text] [Related]
17. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon.
Oberg K; Norheim I; Alm G
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1475-9. PubMed ID: 2480243
[TBL] [Abstract][Full Text] [Related]
18. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]